Access cutting-edge borderline resectable pancreatic ductal adenocarcinoma treatment through this phase 2 clinical trial at a research site in Buffalo. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Buffalo location
Preparing your pre-screening questions…
Access borderline resectable pancreatic ductal adenocarcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related borderline resectable pancreatic ductal adenocarcinoma treatment provided free
Check if you qualify for this borderline resectable pancreatic ductal adenocarcinoma clinical trial in Buffalo, NY
No-Cost Study Care
Local to Buffalo
Convenient for NY residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This phase II trial tests how well liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) before surgery works in treating patients with pancreatic ductal adenocarcinoma that is close to major blood vessels, but is still potentially removable by surgery (borderline resectable). Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Liposomal irinotecan is a form of the anticancer drug irinotecan that is contained inside very tiny, fat-like particles. Liposomal irinotecan may have fewer side effects and work better than other forms of the drug. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. 5-fluorouracil, a type of antimetabolite, stops cells from making DNA and it may kill tumor cells. Leucovorin, a form of folic acid, is used to lessen the toxic effects of substances that block the action of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent. Giving NALIRIFOX before surgery may improve the chance of successful surgery and decrease the chance of the cancer returning after surgery in patients with borderline resectable pancreatic ductal adenocarcinoma.
Sponsor: Roswell Park Cancer Institute
Yes, this clinical trial (NCT06821997) has an active research site in Buffalo, NY that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for borderline resectable pancreatic ductal adenocarcinoma treatment options in Buffalo, NY, this clinical trial (NCT06821997) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Buffalo research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced borderline resectable pancreatic ductal adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all borderline resectable pancreatic ductal adenocarcinoma clinical trials near you to find additional studies recruiting in your area.
See all alzheimers disease clinical trials recruiting in Buffalo — not just this study.
Browse Alzheimers Disease Trials in Buffalo →